Cytek Biosciences, Inc. (CTKB)

Market Cap	814.08M
Revenue (ttm)	201.21M
Net Income (ttm)	-10.16M
Shares Out	128.81M
EPS (ttm)	-0.08
PE Ratio	n/a
Forward PE	25.45
Dividend	n/a
Ex-Dividend Date	n/a

Volume	533,808
Open	6.04
Previous Close	6.19
Day's Range	6.04 - 6.39
52-Week Range	4.66 - 9.87
Beta	1.46
Analysts	Strong Buy
Price Target	9.17 (+45.1%)
Earnings Date	Nov 5, 2024

About CTKB

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS ...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 23, 2021
• Employees: 676
• Stock Exchange: NASDAQ
• Ticker Symbol: CTKB
• Website: https://cytekbio.com

Analyst Forecast

According to 3 analysts, the average rating for CTKB stock is "Strong Buy." The 12-month stock price forecast is $9.17, which is an increase of 45.10% from the latest price.

Price Target

$9.17

(45.10% upside)

Analyst Consensus: Strong Buy